Quick View
| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥155.3B | ¥152.8B | +1.7% |
| Operating Income | ¥5.6B | ¥5.4B | +3.3% |
| Ordinary Income | ¥5.8B | ¥5.5B | +4.9% |
| Net Income | ¥2.9B | ¥3.7B | −19.5% |
| ROE | 2.5% | 3.2% | - |
Executive Summary
FY2025 Q3 cumulative results show revenue of 155.3B yen (YoY +1.7%), operating income of 5.6B yen (YoY +3.3%), ordinary income of 5.8B yen (YoY +4.9%), and net income of 2.9B yen (YoY -19.5%). The company achieved modest top-line growth and operating profit expansion, but net income declined significantly due to extraordinary losses of 1.3B yen and an effective tax rate of approximately 34.8%. Total assets increased to 171.0B yen from 164.5B yen, while equity rose to 117.1B yen from 113.9B yen, maintaining solid financial health with a debt-to-equity ratio of 0.46 and current ratio of 206.0%.
Performance Drivers
Revenue increased 2.5B yen (1.7%) to 155.3B yen, driven primarily by the Dispensing Pharmacy segment which grew 249.5M yen to 8.8B yen. The Clinical Testing segment remained essentially flat at 5.9B yen (down 12.2M yen), while the Medical Devices and Maintenance segment expanded to 738.6M yen in external sales (up 84.9M yen from 653.8M yen). The Other segment declined to 66.1M yen from 129.9M yen, reflecting reduced software sales and maintenance revenue. Operating income increased 186M yen (3.3%) despite relatively modest revenue growth, indicating improved cost management. The Clinical Testing segment's operating profit decreased to 219.4M yen from 223.2M yen, while the Dispensing Pharmacy segment's operating profit increased to 615.0M yen from 537.1M yen. The Medical Devices and Maintenance segment's operating loss narrowed to 1.8M yen from 3.3M yen. Corporate expenses increased to 326.1M yen from 318.4M yen. The gap between ordinary income (5.8B yen) and net income (2.9B yen) of 2.9B yen is substantial, representing 50% compression. This is primarily attributable to extraordinary losses of 1.3B yen and an elevated tax burden with an effective tax rate of 34.8%, resulting in income tax expense of approximately 1.6B yen. The pattern represents revenue up/profit down when comparing operating performance to bottom-line results, though operating income itself improved year-over-year.
Segment Analysis
The Dispensing Pharmacy segment is the core business, accounting for 56.9% of total segment revenue and 73.9% of segment operating profit. Revenue reached 8.8B yen with operating income of 615.0M yen, delivering an operating margin of 7.0%. The Clinical Testing segment generated revenue of 5.9B yen with operating income of 219.4M yen, representing an operating margin of 3.7%, lower than the Dispensing Pharmacy segment. The Medical Devices and Maintenance segment recorded revenue of 1.2B yen (including internal sales) but remained marginally unprofitable with an operating loss of 1.8M yen. The Other segment contributed revenue of 80.0M yen with operating income of 45.5M yen, achieving the highest operating margin at approximately 56.9%, though on a small revenue base. The 4.0 percentage point margin gap between the Clinical Testing (3.7%) and Dispensing Pharmacy (7.0%) segments indicates material profitability differences, with the Dispensing Pharmacy business demonstrating superior operational efficiency.
Key Metrics
[Profitability] Operating margin of 3.6% reflects the impact of corporate expenses, while segment-level margins range from 3.7% in Clinical Testing to 7.0% in Dispensing Pharmacy. Net profit margin stands at 1.9%, compressed by extraordinary losses and tax burden. ROE of 2.5% is constrained by the low net profit margin, with DuPont analysis showing net profit margin of 1.9%, asset turnover of 0.908, and financial leverage of 1.46. ROIC of 3.8% indicates below-target capital efficiency. [Cash Quality] Cash and deposits of 34.2B yen provide coverage of 0.95 times short-term debt and current liabilities. Accounts receivable increased to 30.8B yen with DSO extending to approximately 72 days, signaling collection延長. Inventory rose 1.6B yen (29.9%) to 6.9B yen year-over-year. [Investment Efficiency] Asset turnover of 0.908 demonstrates moderate asset utilization. Investment securities increased 1.2B yen (51.6%) to 3.6B yen. [Financial Health] Total equity of 117.1B yen supports a current ratio of 206.0% and quick ratio of 186.9%. Interest-bearing debt of 12.3B yen results in a debt-to-capital ratio of 9.5% and debt-to-equity ratio of 0.46, indicating conservative leverage. Interest coverage ratio of 113.0 reflects strong debt service capacity.
Cash Flow Analysis
Cash and deposits increased 4.0B yen year-over-year to 34.2B yen, supported by operating profit generation. Working capital expanded as accounts receivable grew 4.9B yen to 30.8B yen and inventories increased 1.6B yen to 6.9B yen, together absorbing approximately 6.5B yen of cash. Accounts payable increased 1.2B yen to 12.5B yen, partially offsetting working capital expansion through extended supplier payment terms. Net working capital stands at 38.4B yen. Total assets expanded 6.5B yen to 171.0B yen, with equity increasing 3.2B yen to 117.1B yen, suggesting net cash generation after accounting for capital expenditures and distributions. Investment securities grew 1.2B yen, indicating deployment of excess cash into financial assets. The company maintains adequate liquidity with cash coverage of short-term liabilities at 0.95 times, though the extension of receivables collection (DSO 72 days) and inventory buildup warrant monitoring for potential working capital efficiency deterioration.
Earnings Quality
Ordinary income of 5.8B yen versus operating income of 5.6B yen shows non-operating net contribution of approximately 233M yen, comprising primarily financial income. Non-operating income represents 0.15% of revenue, consisting of interest and dividend income and other financial gains. The gap between ordinary income (5.8B yen) and net income (2.9B yen) of 2.9B yen is material, with extraordinary losses of 1.3B yen and income tax expense of approximately 1.6B yen accounting for this compression. The effective tax rate of 34.8% and tax burden coefficient of 0.639 indicate elevated tax impact on earnings. While extraordinary losses are disclosed as non-recurring factors, the absence of operating cash flow data limits assessment of earnings quality through cash conversion. The extension of DSO to 72 days and inventory increase of 29.9% year-over-year raise concerns about the timing and quality of cash realization from reported earnings.
Guidance Update
Full-year guidance projects revenue of 206.8B yen (YoY +2.8%), operating income of 7.75B yen (YoY +9.9%), ordinary income of 7.71B yen (YoY +8.9%), and net income of 5.05B yen. Q3 cumulative progress rates are: revenue 75.1%, operating income 72.1%, ordinary income 75.2%, and net income 57.3%. Revenue and ordinary income progress align closely with the standard 75% benchmark for Q3, indicating on-track performance. Operating income progress of 72.1% is slightly below standard, suggesting modest Q4 acceleration is needed. Net income progress of 57.3% is materially below standard, reflecting the impact of Q3 extraordinary losses. The company assumes Q4 net income recovery to approximately 2.2B yen to achieve full-year guidance, implying no recurrence of Q3 extraordinary losses and normalization of the tax rate. The full-year net income guidance of 5.05B yen represents recovery from Q3's 2.9B yen cumulative result, predicated on fourth-quarter operational improvement and absence of additional one-time charges.
Shareholder Returns
Annual dividend of 23.00 yen per share is planned, representing a calculated payout ratio of approximately 33.6% based on full-year net income guidance of 5.05B yen (EPS 162.13 yen) and current Q3 cumulative net income of 2.9B yen. The payout ratio remains within sustainable levels under normal circumstances. No share buyback activity is disclosed. The total return ratio equals the dividend payout ratio of 33.6% in the absence of buyback programs. Dividend sustainability depends on achievement of full-year net income guidance and adequate operating cash flow generation, which cannot be fully assessed without cash flow statement disclosure for the quarterly period.
Risk Factors
Working capital management risk: Accounts receivable increased with DSO extending to 72 days while inventory rose 29.9% year-over-year, indicating potential cash conversion delays. If collection periods continue to lengthen or inventory turnover deteriorates further, operating cash generation could be materially impacted, constraining financial flexibility despite current liquidity strength.
Earnings volatility from non-recurring items: Extraordinary losses of 1.3B yen compressed net income by approximately 45% this quarter, with effective tax rate of 34.8% adding further pressure. Recurring exposure to one-time charges or tax rate variability could sustain bottom-line volatility and complicate earnings predictability.
Low profitability and capital efficiency: Operating margin of 3.6%, ROE of 2.5%, and ROIC of 3.8% all indicate below-benchmark performance relative to industry standards. Without margin expansion through pricing power, cost reduction, or business mix improvement, the company faces challenges in generating adequate returns on deployed capital to support growth investments and shareholder returns.
Industry Benchmark (Reference - Proprietary Data)
[Industry Position] (Reference - Proprietary Analysis)
The company operates in a healthcare services context with mixed segment exposure including clinical testing, dispensing pharmacy, and medical devices. While not a pure IT/Telecom player, available benchmark data provides directional context. Profitability metrics show material gaps: Operating margin of 3.6% falls significantly below the industry median of 8.0% (IQR: 3.4%-17.4%), positioning the company in the lower quartile. Net profit margin of 1.9% is well below the industry median of 5.6% (IQR: 2.2%-12.0%), indicating substantial room for improvement. ROE of 2.5% materially underperforms the industry median of 8.2% (IQR: 3.5%-13.3%), placing the company in the bottom tier of capital efficiency. ROA of 1.7% (calculated) compares unfavorably to the industry median of 4.2% (IQR: 1.4%-7.0%). Revenue growth of 1.7% lags the industry median of 10.5% (IQR: -1.6%-20.5%), reflecting more mature business dynamics. Financial health indicators are comparatively strong: Equity ratio of approximately 68.5% (implied from financial leverage) exceeds the industry median of 59.5% (IQR: 43.7%-72.8%), indicating conservative capitalization. Current ratio of 206.0% surpasses the industry median of 2.13 (IQR: 1.56-3.58), demonstrating superior liquidity. Operational efficiency shows mixed results: Asset turnover of 0.908 exceeds the industry median of 0.68 (IQR: 0.52-0.95), suggesting relatively efficient asset utilization. Receivables turnover (DSO) of 72 days compares to industry median of 60.5 days (IQR: 46-80 days), indicating slightly slower collection. Overall, the company demonstrates strong financial stability and adequate asset efficiency but faces significant profitability and growth challenges relative to broader industry benchmarks.
※ Industry: IT/Telecom sector (99 companies), Comparison: FY2025 Q3 period, Source: Proprietary analysis
Key Takeaways from Earnings
Financial fortress with profitability challenge: The company maintains exceptionally strong financial health metrics including current ratio of 206.0%, debt-to-capital ratio of 9.5%, and interest coverage of 113.0, providing substantial defensive positioning and financial flexibility. However, this financial strength contrasts sharply with weak profitability metrics (operating margin 3.6%, ROE 2.5%, ROIC 3.8%), all materially below industry benchmarks, indicating the company has not effectively deployed its strong balance sheet to generate competitive returns. The key earnings observation is the strategic opportunity to leverage financial capacity for margin-enhancing initiatives.
Bottom-line volatility masks operational stability: While net income declined 19.5% year-over-year due to extraordinary losses of 1.3B yen and elevated tax burden (effective rate 34.8%), operating income grew 3.3% on modest revenue growth of 1.7%, demonstrating underlying operational resilience. The Dispensing Pharmacy segment, representing 57% of revenue and 74% of segment profit, delivered strong performance with operating income increasing to 615M yen from 537M yen. This divergence between operating and net income trends suggests earnings quality assessment should focus on recurring operational performance rather than bottom-line volatility driven by transitory factors.
Working capital dynamics require monitoring: Accounts receivable increased with DSO extending to 72 days while inventory grew 29.9% year-over-year, together absorbing significant cash despite operating profit growth. These working capital trends, if sustained, could constrain cash conversion efficiency and impact the sustainability of the 33.6% dividend payout ratio. The company's full-year guidance implies Q4 net income of approximately 2.2B yen to reach 5.05B yen target, requiring both absence of extraordinary items and improved working capital management to support cash realization of earnings.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.
AI Financial Analysis
Executive Summary
FY2026 Q3 results showed modest top-line and operating-profit growth, but attributable earnings declined materially because of a sizeable extraordinary loss. Revenue increased 1.7% YoY to ¥15.53bn. Operating income rose 3.3% YoY to ¥559m. Ordinary income increased 4.9% YoY to ¥580m. The operating margin improved by approximately 6bp YoY to 3.6% from 3.5%. Gross margin declined by approximately 27bp to 30.2%, indicating modest pressure in procurement, dispensing, or service-delivery costs. However, SG&A as a percentage of revenue fell by approximately 33bp, more than offsetting the gross-margin compression and supporting the operating-margin improvement. Net income attributable to owners fell 21.3% YoY to ¥289m, despite the improvement in ordinary income. The primary reason was a ¥129m extraordinary loss, versus only ¥1m in extraordinary loss in the prior-year period. This extraordinary item reduced profit before tax to ¥452m, down 18.4% YoY. Net margin consequently fell to 1.9%, which is low for a company with a substantial recurring healthcare-services base. The effective tax rate was 34.8%, and the tax burden of 0.639 also restrained conversion of pre-tax income into net income. The pharmacy segment remained the principal earnings contributor, generating ¥615m of segment profit and accounting for roughly 70% of aggregate segment profit before corporate costs. The medical-device sales and maintenance segment expanded revenue strongly, but remained loss-making at the segment level. The balance sheet remains conservatively financed, with a 206.0% current ratio, 0.46x D/E ratio, and 113.0x interest coverage. Full-year revenue and ordinary-income progress is broadly in line with the seasonal benchmark, whereas operating-income progress is modestly behind and net-income progress is substantially below it because of the extraordinary loss. Management's full-year earnings target therefore requires a stronger final quarter, particularly in operating profit and the absence of further non-recurring charges.
Profitability Analysis
The annualized DuPont ROE is 3.3%, comprising a 1.9% net profit margin, 1.211x asset turnover, and 1.46x financial leverage. The weak component is the net profit margin, rather than leverage: the company is conservatively capitalized and does not use financial leverage aggressively to support returns. The annualized ROA is approximately 2.3%, based on annualized Q3 net income and average total assets, also indicating low earnings generation from the asset base. Operating profitability improved slightly, as the 3.6% EBIT/operating margin was about 6bp higher YoY. This improvement was driven by SG&A discipline, with SG&A rising only 0.5% YoY against 1.7% revenue growth, while gross margin contracted by about 27bp. The operating-margin level remains a material concern under the quality alert: EBIT margin of 3.6% is below the 5% concern threshold. In root-cause terms, the group operates businesses with structurally limited margins, notably dispensing pharmacies and clinical testing, while the medical-device segment remains loss-making. In industry context, clinical testing and pharmacy operations can be characterized by reimbursement pricing, labor costs, and procurement-cost pressures; nevertheless, the current margin leaves limited buffer against wage inflation or reimbursement revision. The impact is that even small cost or volume disruptions can have a disproportionate effect on net income and returns. Interest coverage of 113.0x confirms that financing costs are not the source of low profitability. The 5-factor DuPont tax burden was 0.639 and interest burden 0.809; the latter reflects the material difference between EBIT and pre-tax income caused principally by the extraordinary loss rather than recurring interest expense. The decline in attributable profit therefore appears predominantly non-recurring at this stage, while the low underlying operating margin is the more persistent profitability issue.
Growth Assessment
Revenue growth of 1.7% YoY was modest but positive. The pharmacy business was the main source of reported growth, with revenue rising 2.9% YoY to ¥8.81bn and segment profit increasing 14.5% to ¥615m. Clinical testing revenue declined 0.2% YoY to ¥5.92bn and segment profit declined 1.7% to ¥219m, indicating a relatively flat core service trend. The pharmacy operation is the core business on segment operating-income contribution, while it also represents the largest reported revenue stream. Medical-device sales and maintenance revenue grew 13.0% YoY to ¥739m, but the segment recorded a ¥18m loss, albeit narrower than the prior-year ¥33m loss. The other software sales and maintenance business contracted sharply, with revenue down 49.1% YoY to ¥66m and segment profit down 54.4% to ¥45m; its small scale limits its group impact. Segment-profit growth before corporate costs was 9.9% YoY, exceeding the 3.3% growth in consolidated operating income because corporate costs increased 2.4% to ¥326m. The pharmacy segment's segment margin improved to approximately 7.0% from 6.3%, whereas clinical testing remained around 3.7% and medical devices remained slightly negative. Full-year guidance calls for revenue of ¥20.69bn, up 2.8% YoY, operating income of ¥775m, up 9.9%, and ordinary income of ¥771m, up 8.9%. Q3 cumulative revenue progress is 75.1%, essentially in line with the standard 75% benchmark. Ordinary-income progress is 75.2%, also in line with the benchmark. Operating-income progress is 72.2%, 2.8 percentage points below the benchmark, requiring a comparatively stronger Q4 operating result. Attributable-profit progress is 57.2% against the full-year ¥505m target, 17.8 percentage points below the 75% benchmark, reflecting the extraordinary loss and making the bottom-line target more execution-sensitive.
Financial Health
Liquidity is strong, with current assets of ¥7.45bn against current liabilities of ¥3.62bn, producing a 206.0% current ratio. The 186.9% quick ratio shows that liquidity is not dependent on inventory liquidation. Cash and deposits of ¥3.42bn cover approximately 95% of current liabilities, while receivables of ¥3.08bn provide additional near-term liquidity. Working capital was ¥3.84bn. The current ratio is well above 1.0x, so there is no current-liquidity warning or apparent maturity mismatch between current assets and current obligations. Solvency is also sound: reported D/E is 0.46x, debt/capital is 9.5%, and interest coverage is 113.0x. These measures are materially below the 2.0x D/E warning level and indicate ample debt-servicing capacity. Total equity increased to ¥11.71bn from ¥11.39bn a year earlier, supported by retained earnings and positive valuation differences on securities. Equity represented approximately 68.5% of total assets, providing substantial loss-absorption capacity. The asset base is capital intensive, with property, plant and equipment representing 50.7% of total assets, including ¥3.37bn of land and a substantial building base. This makes asset utilization and maintenance efficiency important to returns, even though balance-sheet leverage is conservative. Inventories increased ¥159m, or 29.9% YoY, to ¥690m; the rise warrants monitoring for inventory turnover and potential obsolescence, particularly in finished goods. Investment securities increased ¥121m, or 51.6% YoY, to ¥356m, increasing exposure to market-value movements, although the absolute balance remains only 2.1% of total assets. No segment-level impairment or goodwill was reported.
Notable B/S Changes
Inventories: +¥159m (+29.9%) to ¥690m - growth exceeded revenue growth and should be monitored for turnover, demand alignment, and finished-goods obsolescence risk. Investment securities: +¥121m (+51.6%) to ¥356m - increases exposure to market-price fluctuations, although the balance remains modest at 2.1% of total assets.
Cash Flow Quality
Dividend Sustainability
The full-year dividend forecast is ¥23 per share. Against forecast EPS of ¥162.13, the implied dividend payout ratio is approximately 14.2%. This is a low payout ratio and leaves a substantial earnings buffer under the stated forecast. Net assets of ¥11.71bn and the conservative debt profile further support financial flexibility. The company reported no interim Q2 dividend, so the indicated shareholder distribution is concentrated in the year-end payment. The principal factor for monitoring is achievement of the ¥505m full-year attributable-profit forecast, since Q3 cumulative attributable profit was only ¥289m following the extraordinary loss. Even if earnings recovery is slower than planned, the low indicated dividend payout ratio provides a meaningful cushion.
Risk Assessment
Business risks include Reimbursement and regulatory risk: clinical testing and dispensing pharmacy operations can be affected by revisions to medical-fee and drug-price reimbursement schedules, which could pressure already low operating margins., Labor-cost inflation and pharmacist/medical-technician availability: personnel-intensive healthcare services have limited capacity to absorb wage inflation when the consolidated operating margin is only 3.6%., Clinical testing volume and customer concentration risk: flat clinical-testing revenue and declining segment profit indicate limited current growth momentum in this business., Medical-device execution risk: revenue increased 13.0% YoY, but the segment remained loss-making, creating risk that growth is not translating into acceptable returns., Inventory risk: finished-goods inventory increased 29.9% YoY, requiring monitoring of demand alignment, turnover, and possible markdown or obsolescence exposure..
Financial risks include Extraordinary-loss recurrence risk: the ¥129m extraordinary loss was large relative to Q3 operating income of ¥559m and materially reduced net-income conversion., Low-return risk: annualized ROE of 3.3% and annualized ROA of approximately 2.3% indicate limited earnings productivity from the capital base., Investment-security valuation risk: investment securities rose 51.6% YoY, and positive securities valuation differences contributed to comprehensive income., Asset-intensity risk: PPE accounts for 50.7% of total assets, increasing the importance of utilization rates and the risk of future disposal or impairment charges if operating locations underperform..
Key concerns include Highest priority: sustaining and expanding the 3.6% operating margin, because low operating efficiency provides little buffer against cost inflation or reimbursement pressure., High priority: recovery in Q4 attributable profit, as progress to the full-year profit forecast is 57.2% versus a 75% seasonal benchmark., Medium priority: conversion of medical-device revenue growth into positive segment profit., Medium priority: normalization of inventory growth and prevention of working-capital buildup..
Investment Implications
Key takeaways include Underlying operating earnings improved modestly, with operating income up 3.3% YoY and margin up about 6bp., The pharmacy business is the central earnings engine, combining the largest revenue base with the highest material segment-profit contribution., The decline in net income was driven primarily by a ¥129m extraordinary loss, rather than deterioration in ordinary income., Liquidity, leverage, and interest-servicing capacity are strong., Structural profitability remains limited, with a 3.6% EBIT margin, 1.9% net margin, and annualized ROE of 3.3%..
Metrics to watch include Consolidated operating margin and gross-margin trajectory, Clinical testing revenue and segment-profit recovery, Pharmacy segment margin sustainability, Medical-device segment break-even progress, Q4 operating income needed to meet ¥775m full-year guidance, Further extraordinary gains or losses, Finished-goods inventory growth relative to sales, Investment-security valuation movements.
Regarding relative positioning, The company is financially conservative and has a stable healthcare-service revenue base, but its profitability and annualized capital returns are below broad quality thresholds. Relative positioning is therefore defined more by balance-sheet resilience and pharmacy-segment earnings stability than by high-margin growth or superior return generation.